Search | Clinical Trials Finder

Conditions: Ovarian Cancer
Interventions: Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure; Drug · Biological · Procedure
Lead sponsor: Kalinski, Pawel, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Solid Tumors
Interventions: ALKS 4230, Pembrolizumab; Biological
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 17
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Malignant Neoplasm
Interventions: MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota

Conditions: Non Muscle Invasive Bladder Cancer
Interventions: CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside; Biological · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: La Jolla, California • Orange, California • Tampa, Florida + 9 more

Conditions: Soft Tissue Sarcoma Adult
Interventions: Multiple drug microinjection, CIVO device; Drug · Device
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Lake Success, New York • Portland, Oregon • Seattle, Washington

Conditions: Metastatic Cancer
Interventions: Keytruda Injectable Product, Yervoy Injectable Product, GM-CSF, Non-ablative Cryosurgical freezing; Drug · Procedure
Lead sponsor: ImmunSYS, LLC; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Scottsdale, Arizona • Miami Lakes, Florida

Conditions: Locally Advanced/Metastatic Solid Tumors
Interventions: BJ-001, Pembrolizumab; Drug
Lead sponsor: BJ Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: St Louis, Missouri • New York, New York • Greenville, South Carolina + 2 more

Conditions: NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
Interventions: CJRB-101, Pembrolizumab injection; Drug
Lead sponsor: CJ Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Irvine, California • Pittsburgh, Pennsylvania

Conditions: Solid Tumor
Interventions: Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 9
States / cities: Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more

Conditions: Pancreatic Cancer
Interventions: Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab, IMC-CS4; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumor
Interventions: DB-1305/BNT325, Pembrolizumab, BNT327; Drug · Combination Product
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 42
States / cities: Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Docetaxel, Gemcitabine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Questionnaire Administration, Sacituzumab Govitecan; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 162
States / cities: Phoenix, Arizona • Irvine, California • Orange, California + 127 more

Conditions: Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nivolumab, Obinutuzumab, Pembrolizumab, Positron Emission Tomography, Rituximab, Romidepsin, Saline, Trastuzumab; Drug · Biological · Other + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Decitabine, Pembrolizumab, Venetoclax; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Melanoma Stage III, Melanoma Stage IV
Interventions: L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®; Drug
Lead sponsor: Philogen S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Hartford, Connecticut • New York, New York

Conditions: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
Interventions: BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly; Drug
Lead sponsor: BioInvent International AB; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Philadelphia, Pennsylvania

Conditions: NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung Cancer (NSCLC), Metastatic NSCLC - Non-Small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions: Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more

Conditions: Neoplasms
Interventions: GSK1795091, GSK3174998, GSK3359609, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boston, Massachusetts • St Louis, Missouri • Dallas, Texas + 2 more

Conditions: Melanoma
Interventions: Talimogene Laherparepvec, Pembrolizumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
Interventions: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy, Recombinant Flt3 Ligand, Pembrolizumab, Tocilizumab; Biological · Drug · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions: Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 55
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 42 more

Search by objective public record fields.

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Metastatic Solid Cancer Clinical Trial

Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)